Abstract
Background/Objective Cortical spreading depolarization (SD) is increasingly recognized as a major contributor to secondary brain injury. Noninvasive SD monitoring would enable the institution of SD-based therapeutics. Our primary objective is to establish proof-of-concept validation that scalp DC-potentials can provide noninvasive SD detection by comparing scalp direct-current (DC)-shifts from a high-density electrode array to SDs detected by gold-standard electrocorticography (ECoG). Our secondary objective is to assess usability and artifact tolerance.
Methods An 83×58 mm thermoplastic elastomer array with 29 6-mm diameter Ag/AgCl 1-cm spaced electrodes, the CerebroPatch™ Proof-of-Concept Prototype, was adhesively placed on the forehead with an intervening electrode gel interface to record DC-electroencephalography in normal volunteers and severe acute brain injury patients in the neuro-intensive care unit some with and some without invasive ECoG electrodes. The scalp and ECoG voltages were collected by a Moberg® Advanced ICU Amplifier. Artifacts were visually identified and usability issues were recorded. SD was scored on ECoG based on DC-shifts with associated high-frequency suppression and propagation. A six-parameter Gaussian plus quadratic baseline model was used to estimate ECoG and scalp electrode time-courses and scalp-voltage heat-map movies. The similarity of the noninvasive scalp and invasive ECoG DC-shift time-courses was compared via the Gaussian fit parameters and confirmed if the Coefficient-of-Determination was >0.80.
Results Usability and artifact issues obscured most scalp Prototype device data of the 140 ECoG-coded SDs during 11 days in one sub-arachnoid hemorrhage patient. Twenty-four of these DC-shifts were in readable, artifact-free portions of scalp recordings and had a >0.80 Coefficient-of-Determination (0.98[0.02], median[IQR]) between invasive ECoG and noninvasive Prototype device DC-shifts. These data suggest that these scalp DC-shifts (peak -457±69 µV [mean±StD], full-width-half maximum 70.9±5.92 sec, area 18.7±2.76 cm2) depicted in the heat-map movies represent noninvasively detected SDs.
Conclusions These results suggest that noninvasive SD detection is possible using scalp DC-potential signals with a high spatial resolution EEG array. Efforts to limit artifact and improve usability in DC-EEG detection are needed to enable multi-modal monitoring for secondary brain injury.
Competing Interest Statement
Stephen C. Jones and Samuel J. Hund are founding partners and shareholders of CerebroScope. Benjamin R. Brown is a consultant to and shareholder of CerebroScope and Eric L. Singer is a shareholder of CerebroScope.
Funding Statement
This project was conducted for CerebroScope, a medical device company developing a scalp DC-EEG system for detecting SDs in sABI, concussion, and migraine. This work was partially supported by grants from the: US Public Health Service National Institutes of Health: NS30839, NS30839-14S1 and NS66292 to the SCJ while at the Allegheny-Singer Research Institute; and 5R43NS092181 and 3R43NS092181-02S1 to SCJ for CerebroScope.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of the University of New Mexico Human Research Protections Office gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This second version of the manuscript has been revised with extensive changes after successive coauthor reviews and an expanded supplemental video has been supplied.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
